百时美施贵宝Bristol Myers Squibb（BMY）2025年第一季度业绩报告「NYSE」（英文版）（19页）.pdf

1、 1 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution First quarter revenues were$11.2 billion,-6%(-4%Ex-FX)Growth Portfolio revenues were$5.6 billion,+16%(+18%Ex-FX)GAAP EPS was$1.20 and non-GAAP EPS wa

2、s$1.80 Raising 2025 revenue guidance to a range of$45.8 billion to$46.8 billion;Increasing non-GAAP EPS range to$6.70 to$7.00 (PRINCETON,N.J.,April 24,2025)Bristol Myers Squibb(NYSE:BMY)today reports results for the first quarter of 2025.“Our strong execution in the first quarter drove continued mom

3、entum across our Growth Portfolio and meaningful progress in the pipeline,”said Christopher Boerner,Ph.D.,board chair and chief executive officer,Bristol Myers Squibb.“We are advancing our multi-year plan to become a more agile and efficient company,while strengthening the foundation for top-tier,lo

4、ng-term growth.Our strategy is clear,and our actions are accelerating the delivery of transformational medicines to patients.First Quarter Results$in millions,except per share amounts 2025 2024 Change Change Excl.FX*Total Revenues$11,201$11,865 (6)%(4)%Earnings/(Loss)Per Share-GAAP*1.20 (5.89)N/A N/

5、A Earnings/(Loss)Per Share-Non-GAAP*1.80 (4.40)N/A N/A Acquired IPRD Charge and Licensing Income Net Impact on Earnings/(Loss)Per Share (0.04)(6.30)N/A N/A*GAAP and Non-GAAP earnings/(loss)per share include the net impact of Acquired IPRD charges and licensing income.*See Use of Non-GAAP Financial I

6、nformation.2 FIRST QUARTER RESULTS All comparisons are made versus the same period in 2024 unless otherwise stated.Total revenues of$11.2 billion decreased 6%,or 4%Ex-FX.U.S.revenues of$7.9 billion decreased 7%.International revenues of$3.3 billion decreased 2%,or increased 2%Ex-FX.Growth Portfolio